Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study
Objective: To examine whether the response to an inhaled levodopa formulation (CVT-301; at 35 and 50 mg per dose) is dependent on baseline patient characteristics.…Characterization of burning mouth syndrome in patients with Parkinson’s disease
Objective: To determine the prevalence and characteristics of burning mouth syndrome (BMS) in a Parkinson's disease (PD) population through a self-administered survey. Background: The majority…Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms
Objective: We investigated whether intrastriatal injection of ionomycin to hemiParkinsonian rats produced changes in L-DOPA responses including LID and analyzed the effects of ionomycin on…Prevalence of orthostatic hypotension after a low subacute levodopa dose in patients with parkinsonism
Objective: To evaluate the prevalence of orthostatic hypotension (OH) after a low subacute levodopa (LD) dose in patients with diagnosis of Parkinson's disease (PD) or…Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey
Objective: To assess socio-demographic and disease specific data in patients with Parkinson's disease (PD) before and one year after therapy escalation with subcutaneous apomorphine (APO),…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry
Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…
- « Previous Page
- 1
- …
- 55
- 56
- 57